Although chimeric antigen receptor (CAR)-T cell therapies are typically administered in the inpatient setting, outpatient administration is rapidly expanding. However, there is limited summarized evidence comparing outcomes between outpatient and inpatient administration. This systematic literature review aims to compare the safety, efficacy, quality of life (QoL), costs, and healthcare resource utilization (HCRU) outcomes in patients with hematological cancer who are administered CAR-T therapy in an outpatient versus an inpatient setting. Publications (2016 or later) that reported the outcomes of interest in patients treated with a CAR-T therapy in both outpatient and inpatient settings, or only the outpatient setting, were reviewed. In total, 38 publications based on 21 studies were included. Safety findings suggested the comparable frequency of adverse events in the two settings. Eleven studies that reported data in both settings showed comparable response rates (80–82% in outpatient and 72–80% in inpatient). Improvements in the QoL were observed in both settings while costs associated with CAR-T therapy were lower in the outpatient setting. Although unplanned hospitalizations were higher in the outpatient cohort, overall HCRU was lower. Outpatient administration of CAR-T therapy appears to have comparable outcomes in safety, efficacy, and QoL to inpatient administration while reducing the economic burden.
尽管嵌合抗原受体（CAR）-T细胞疗法通常在医院住院环境中实施，但门诊给药模式正在迅速扩展。然而，目前比较门诊与住院给药效果的系统性证据仍较为有限。本系统性文献综述旨在比较血液肿瘤患者在门诊与住院环境下接受CAR-T治疗的安全性、疗效、生活质量（QoL）、治疗成本及医疗资源利用（HCRU）的差异。研究筛选了2016年及之后发表的文献，这些文献报告了在门诊和住院两种环境中接受CAR-T治疗患者的结局数据，或仅涉及门诊环境的数据。最终共纳入基于21项研究的38篇文献。安全性数据显示两种环境下不良事件发生率相当。11项同时报告两种环境数据的研究显示治疗应答率相近（门诊为80–82%，住院为72–80%）。两种环境下患者生活质量均有所改善，而门诊环境下的CAR-T治疗相关成本更低。尽管门诊组患者的非计划性住院率较高，但总体医疗资源利用率更低。研究表明，CAR-T疗法的门诊给药在安全性、疗效和生活质量方面与住院给药相当，同时能减轻经济负担。
肿瘤(癌症)患者之家